Comments on: Mundipharma and Purdue reach a new deal to in-licence from ESTEVE full global rights and development responsibilities for novel first-in-class sigma-1 antagonist (S1A or MR309/E-52862)

Comments on: Mundipharma and Purdue reach a new deal to in-licence from ESTEVE full global rights and development responsibilities for novel first-in-class sigma-1 antagonist (S1A or MR309/E-52862) https://www.novumpr.nl/2016/05/17/mundipharma-and-purdue-reach-a-new-deal-to-in-licence-from-esteve-full-global-rights-and-development-responsibilities-for-novel-first-in-class-sigma-1-antagonist-s1a-or-mr309e-52862/?utm_source=rss&utm_medium=rss&utm_campaign=mundipharma-and-purdue-reach-a-new-deal-to-in-licence-from-esteve-full-global-rights-and-development-responsibilities-for-novel-first-in-class-sigma-1-antagonist-s1a-or-mr309e-52862 NovumPR press releases Tue, 17 May 2016 07:19:03 +0000 hourly 1 https://wordpress.org/?v=6.8.3